Bastiaan Sallevelt

86 CHAPTER 2.2 Table SI1.1. Continued. STOPP Action Clarity rating Condition Clarity rating Explanation Clarity rating E5 Colchicine 100% if eGFR < 10 ml/min/1.73m2 100% (risk of colchicine toxicity). 83% E6 Metformin 100% if eGFR < 30 ml/min/1.73m2 100% (risk of lactic acidosis). 83% F F1 Prochlorperazine or metoclopramide 100% with Parkinsonism 92% (risk of exacerbating Parkinsonian symptoms). 92% F2 PPI 58% for uncomplicated peptic ulcer disease or erosive peptic oesophagitis at full therapeutic dosage for > 8 weeks 50% (dose reduction or earlier discontinuation indicated). 33% F3 Drugs likely to cause constipation (e.g. antimuscarinic/anticholinergic drugs, oral iron, opioids, verapamil, aluminium antacids) 33% in patients with chronic constipation where nonconstipating alternatives are available 67% (risk of exacerbation of constipation). 100% F4 Oral elemental iron doses greater than 200 mg daily (e.g. ferrous fumarate> 600 mg/day, ferrous sulphate > 600 mg/day, ferrous gluconate> 1800 mg/day; 50% 100% (no evidence of enhanced iron absorption above these doses). 75% G G1 Theophylline 100% as monotherapy for COPD 75% (safer, more effective alternative; risk of adverse effects due to narrow therapeutic index). 75%